GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--Aug. 9, 2024--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of June 26, 2024, the compensation committee of GeneDx's board of directors granted seven newly hired employees 75,100 restricted stock units ("RSUs") as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx's 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年8月9日--康涅狄格州斯坦福--(BUSINESS WIRE)--GeneDx (纳斯达克: WGS)是通过基因组洞见提供改进健康成果的领导者，今天宣布，自2024年6月26日起，GeneDx的董事会的薪酬委员会授予七名新员工75,100个限制性股票单位(RSUs)，作为每个进入GeneDx雇佣的员工的诱因资料。这些RSU是根据GeneDx的2023年股权诱因计划授予的，并符合纳斯达克上市规则5635(c)(4)。
The inducement RSUs will vest in equal annual installments over the four-year period following the grant date, subject to the employee's continued service with the Company on each applicable vesting date.
诱因RSUs将在授予日后的四年内平均每年分期归属，前提是员工在每个可适用的归属日继续在公司服务。
Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement. Typically, upon full vesting, shares are sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs and funded by a "sell to cover" transaction. This does not represent a discretionary transaction by the Reporting Person.
每个RSU代表了一项在结算时有条件获得发行人A类普通股1股的权利。通常，在完全归属时，股票会被出售以支付与RSUs的归属和结算相关的税款保留义务，而这些股票由"卖出以支付"交易资助。此举不代表举报人的自由裁量权。
About GeneDx
关于GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
在GeneDx (纳斯达克:WGS) ,我们认为每个人都应该得到个性化的、有针对性的医疗保健——而这一切都始于基因诊断。受世界上最大的罕见病数据集之一的推动，我们行业领先的外显子组和基因组测试将复杂的基因组数据转化为临床答案，从而解锁个性化健康计划，加速药物发现，并提高卫生系统效率。这一切都始于一次简单的测试。欲了解更多信息，请访问genedx.com，并通过 LinkedIn 、X、Facebook和Instagram与我们联系。
View source version on businesswire.com:
请查看商业线(businesswire.com)的源版本。
Investor Relations Contact:
investors@GeneDx.com
投资者关系联系人：
investors@GeneDx.com
Media Contact:
press@GeneDx.com
媒体联系人：
press@GeneDx.com
Source: GeneDx
来源：GeneDx